Skip to main content



shares rose early Monday after the biotech company said federal regulators had given it a 90-day extension for the consideration of its cancer drug.

The California-based company said the Food and Drug Administration made the move after SuperGen submitted additional test data for Orathecin, its investigational drug for the treatment of pancreatic cancer patients who have failed at least one prior chemotherapy regimen.

Scroll to Continue

TheStreet Recommends

SuperGen submitted additional data from the company's trial of Orathecin for use as a first-line pancreatic cancer treatment -- as requested by the FDA -- as well as several new sets of data analysis to further evaluate Orathecin in second- and third-line patients.

"We wanted the agency to have access to the most complete body of clinical data in order to clearly understand the utility of Orathecin," the company said.

Shares rose 7 cents, or 4.3%, to $6.52 in premarket trading.